NightstaRx Boasts Advantage Over Spark In Inherited Retinal Disease
This article was originally published in Scrip
Spun out from the University of Oxford, new born NightstarRx is finding its feet in the biopharma field and has closed a $35m series B funding, with which it will boost its inherited retinal disease pipeline.
You may also be interested in...
Allogene launched a $324m IPO to fund development of its allogeneic CAR-T pipeline, bringing its 2018 fundraising total to $744m. Also, GW Pharma's $345m offering tops recent follow-ons.
The UK developer of gene therapies for inherited eye diseases has listed on NASDAQ, adding to its monetary resources for competing in what is becoming a competitive sector for drug development, and going some way to validating the approach of the UK healthcare investment firm, Syncona, to growing biotech companies.
IPO launches in the US hit a wall in August, but several biopharma firms recently entered the queue, adding new opportunities for investors to chase the industry's outperforming returns.